Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing
Key Highlights
- ➤Nexalin (NXL) regained Nasdaq minimum bid compliance after 21 consecutive days above $1.00.
- ➤Nasdaq Hearings Panel granted continued listing following Nexalin’s reverse stock split.
- ➤Nexalin must demonstrate $2.5 million stockholders’ equity compliance by January 4, 2027.
- ➤Nexalin announced a distribution agreement covering Brazil and six additional South American markets.
- ➤Nexalin continues pivotal HALO Clarity insomnia trial while pursuing U.S. FDA marketing authorization.
Expert Statements
Mark White, Chief Executive Officer of Nexalin
“We appreciate the Panel’s decision and are pleased to have satisfied the bid price requirement”
Mark White, Chief Executive Officer of Nexalin
“Our primary focus remains on the growing momentum across our business.”
Mark White, Chief Executive Officer of Nexalin
“We recently announced a distribution agreement covering Brazil and six additional South American markets, an important step in our transition toward commercial revenue generation, and we continue to advance our U.S. clinical programs, including our pivotal HALO™ Clarity clinical trial in insomnia, as we pursue FDA marketing authorization of our DIFS™ technology in the United States.”
Company remains focused on its transition toward commercial revenue generation and the advancement of its U.S. clinical programs
HOUSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has received written confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Nasdaq confirmed that the closing bid price of the Company’s common stock was above the $1.00 per share minimum for 21 consecutive trading days, from August 31 through September 29, 2026, following the Company’s previously announced reverse stock split.
Get started
Create a free account to read the full story.